+




FIG. 2A







FIG. 2C

















FIG. 3





**FIG. 5** 



+-

7/19

FIG. 6






FIG. 7C FIG. 7B FIG. 7A





30 ☐

20-



80

9

+ o

10-

SLEDAI

Allostimulatory capacity

10/19

FIG. 10






FIG. 11




+

+

FIG. 12





14/19 FIG. 14B 40 Percentage inhibition 30 20 10 70 , 0 09 20 Virus+ anti-TNF mAB Virus+ Isotype control FIG. 14A ☐ 1st culture ☑ 2nd culture Virus 20 -40 -80 J - 09 30 -10 0 20 70 IFN-α ng/ml







FIG. 15



Triggering FIG. 16 agent TNF promotes pDC maturation thus TNF block pDC blocking IFN- $\alpha$  release ontogeny Mature mDC Immature CD34 pDC Autocrine **HPC TNF** Mature mDC\_  $IFN\alpha/\beta$ Monocytes

FIG. 17




FIG. 18




FIG. 19A




FIG. 19B




FIG. 19C







FIG. 19D



an along the state of the state of

## FIG. 20





## FIG. 22

